Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes

Abstract

This study aimed to examine amyloid-beta (A beta) and tau (AT) biological stages, plasma biomarkers, and cognitive trajectories according to AT stages in Alzheimer&apos;s disease-related cognitive impairment (ADCI), subcortical vascular cognitive impairment (SVCI), and frontotemporal dementia (FTD). A total of 275 participants (42 cognitively unimpaired [CU], 132 ADCI, 73 SVCI, and 28 FTD) underwent A beta and tau positron emission tomography for assessment of AT stages. Participants with cognitive impairment (ADCI, SVCI, and FTD) were classified according to clinical stages of mild cognitive impairment or dementia. Plasma biomarkers were analysed, and cognitive trajectories were assessed using mixed-effects models over 6.1 years. SVCI and FTD showed more advanced clinical stages than ADCI at equivalent AT stages. SVCI participants had higher plasma glial fibrillary acidic protein (P = 0.012) and neurofilament light chain (P = 0.025) than CU participants in the A - T- stage. In the A - T- stage, SVCI (beta = -0.738, P = 0.002) and FTD (beta = -4.016, P < 0.001) showed faster cognitive decline than CU, but not ADCI. In the A + T - stage, ADCI (beta = -0.634, P = 0.005) and SVCI (beta = -0.690, P = 0.006) showed faster decline than CU. In the A + T + stage, only ADCI exhibited significantly faster decline than CU (beta = -1.856, P = 0.008). Distinct plasma biomarker profiles and cognitive trajectories characterise ADCI, SVCI, and FTD across AT classification, highlighting the heterogeneity in pathophysiological mechanisms across dementia types.